Brind.

Quest Diagnostics developed the Haystack MRD test, which received FDA breakthrough device designation and is expanding its service locations.

3 reports, 2 independent Updated Aug 26
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Quest Diagnostics developed the Haystack MRD test, which received FDA breakthrough device designation and is expanding its service locations.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Medical Device NetworkFDA grants breakthrough device designation for Quest Diagnostics’ MRD test The US Food and Drug Administration (FDA) has granted breakthrough device designation for Quest Diagnostics’ Haystack minima
  • PR NewswireFDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading pr
  • PR NewswireMass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystac